The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma
Treatment decisions for advanced melanoma are increasingly complex as the landscape quickly evolves. This European expert panel study sought to understand which patient characteristics and disease-related factors inform clinicians' choices of first-line treatment for BRAF-mutated melanoma.
The PRMA Consulting team are excited to launch the inaugural meeting of our expert advisory group focused on #complexpricing. #pharma #biotech
Demonstrating product value through the revised ESMO value framework
This case study outlines the approach taken when a client sought to understand how changes to the ESMO-MCBS would affect the perceived value of their products and how these perceptions aligned with HTA outcomes.
Experience our new digital applications
We warmly invite you to our drinks reception and demonstration of new digital applications at the ISPOR Global Conference in Baltimore, from 6pm on Monday 21 May and Tuesday 22 May on booth 807. This is the ideal opportunity to experience our latest solutions and discuss your specific market access challenges with members of our senior leadership team.
What role does the patient perspective play in determining access to innovative therapies?
Join us at ASCO 2018 to discover more about the differences between the EU and US perspectives on HRQL.
Indication-specific pricing: the obvious solution?
This presentation examines the opportunities and challenges for manufacturers and payers in implementing indication-based pricing strategies. You will gain an understanding of the complexities that multiple indication and combination products present for pricing and reimbursement and obtain actionable insights for developing a value proposition for indication-specific pricing.
Leveraging the value frameworks scoring of a new treatment and comparators
See the approach taken when a client sought to understand how various value frameworks would score their new treatment, in comparison to competitor products, and how this could be leveraged in the value proposition.
Tailored solutions for early planning in market access
Visit booth 29 at DIA Europe and discover how we can help you develop an integrated early evidence strategy that anticipates and navigates complex market access requirements from pre-clinical development and beyond.
Value and Access: striking a balance
Join us in an expert discussion at DIA Europe
Ensuring optimal access at appropriate value is a balancing act. Our senior director, Jan McKendrick, is pleased to be participating in a thought leading discussion at DIA Europe which will address key questions on the topic taking into account multiple perspective. As part of the session, Jan will present international evidence of the impact of reimbursement and licensing discrepancies on patient access before a discussion on harmonisation and the path forward.
Visit booth 29 to discuss this with Jan in more detail.
3 reasons why an expert advisory group can help with your complex pricing challenges
Manufacturers seeking to execute complex pricing schemes rapidly and effectively need to approach payers with well-developed solutions, adapted to a range of country requirements and aligned with the changing landscape. Find out how an expert advisory group can help you with your complex pricing issues
Payer perspectives on cell and gene therapies: 9 key challenges
Assessing payer perspectives on the rapid developments in regenerative medicines and cell therapy, we highlight the key challenges and opportunities for the clinical pipeline.
CAR-Ts therapy and indication-specific pricing in Europe: new insights
A recent meeting of complex pricing experts from across the EU5 countries focused on the variability among countries of payers’ and policy-makers’ attitudes to innovative pricing, and the practical challenges for implementation of complex pricing schemes capable of satisfying a range of country requirements and accommodating the rapidly evolving landscape. We are pleased to share our highlights from this thought-leading meeting.
Insights direct to your inbox
New data protection regulations come into effect this year which mean that you may no longer be among the first to receive our insights for pricing, reimbursement and market access.
Whether you regularly enjoy our thought-leading presentations or just like downloading our case studies and articles from time to time, to continue to receive our updates please let us know now.
Running the half-marathon for Addison's Disease Self-Help Group
A team of colleagues from PRMA Consulting are challenging themselves by running the Fleet half-marathon in March; for one of the group this will be a training run for the Rotterdam marathon a few weeks later!
Through our running, we would like to raise awareness and much needed funds for the Addison's Disease Self-Help Group. We recently became aware of the impact of this disease on a young child and his family; thankfully he survived and is learning to live with his condition.
Launch of the expert advisory group on complex pricing
The PRMA Consulting team are excited to launch the inaugural meeting of our expert advisory group focused on complex pricing. The group will look at recent and emerging US experience with CAR-Ts and evaluate potential pricing models in the EU. We will also discuss the challenges and opportunities to indication-specific pricing in Europe. We will share highlights from this meeting with clients after the holidays.
CAR-Ts: access challenges and opportunities
Following our successful webinar yesterday on ‘Market access considerations for CAR-Ts: insights from ASH’, please find more information about how we can help you with your access challenges and opportunities for CAR-Ts.
Payer perspectives on cell and gene therapies: opportunities and challenges
This new webinar has true cross-functional value for everyone working in market access in the pharmaceutical industry. From non-expert audiences through to subject-matter experts. Professor Stephen Palmer from the University of York will join us to discuss his recent work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.
Patient-centricity: shaping value generation for HTA and market access
With patient-centricity becoming a new paradigm for the pharmaceutical industry, this webinar will examine the role of patient engagement in HTA and market access processes, and how this enhances value generation for drug approvals. Focusing on Europe, we will analyze the different models and guidelines in place.
"Please let your staff who supported us know how appreciative we are of their efforts. From the advisory boards to the GVD development to the modeling efforts and numerous projects, the support and partnership was great. The accomplishment in the UK with NICE is absolutely exceptional."
ISPOR Glasgow is nearly upon us! Join us at booth 404 to discuss your market access challenges
Subscribe now to get the latest updates from PRMA Consulting
Market access update key learnings from ASCO and EHA 2017
In this webinar, we discuss the evolution of value frameworks, the OCM, and incorporating the patient perspective. We also consider the implications for payers of new data on CAR-Ts; key points to think about when planning for market access of a combination; and how payers might handle products approved on the basis of basket trials.
"Just wanted to say great job presenting today. The commercial team increasingly want to be involved in these discussions and your discussion points and delivery were great for the access and broader team. Thanks for making the information practical and insightful. I think the overall response from the team was very positive and the content will ultimately be incredibly helpful for our strategy."
Market access for PD-1 inhibitors: where are we now?
With three products targeting the PD-1 pathway now approved, and other launches expected in 2017, this webinar will take stock of payers’ reactions to the products. Focusing on Europe, we will look at the decisions that have been made to date and discuss these further.